Vaccine Adjuvants Market Worth 769.4 Million USD by 2021

Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021

(EMAILWIRE.COM, July 11, 2018 ) The global vaccine adjuvants market consists of human and veterinary adjuvants that are used to improve the efficacy of vaccines. This market is driven by several factors such as increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on prevention of diseases. The high growth potential in emerging markets has opened an array of opportunities for the market. However, the high cost of adjuvant-based research and proven safety of adjuvants are hampering the growth of the global market.

Browse 90 market data Tables with 42 Figures spread through 156 Pages and in-depth TOC on "Vaccine Adjuvants Market"

http://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html

Early buyers will receive 10% customization on this report.

The major factors driving the growth of this market are high prevalence of infectious and zoonotic diseases, increasing focus on immunization programs by various government bodies, and growing focus on improved and long-lasting immunization against existing and emerging diseases.

The report segments this market into product type, route of administration, disease type, applications, and application categories. On the basis of product type, the Vaccine Adjuvants Market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. Particulate adjuvants are expected to account for the largest share of the market. Adjuvant emulsions, on the other hand, are projected to grow at the highest CAGR from 2016 to 2021 due to factors such as the proven efficacy and relatively fewer safety issues involved in the use of adjuvant emulsions.

Talk To Our Research Experts:

http://www.marketsandmarkets.com/speaktoanalyst.asp?id=152603894

On the basis of route of administration, the Vaccine Adjuvants Market is segmented into oral, subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global Vaccine Adjuvants Market in 2016. The rapidly growing geriatric population and increasing need for development of better vaccines for improved immunization are the key factors propelling the growth of this market.

On the basis of disease type, the Vaccine Adjuvants Market includes infectious diseases, cancer, and other diseases. The infectious diseases segment is expected to account for the largest share of the global Vaccine Adjuvants Market in 2016. High incidences of diseases and research investments in life sciences are the major factors driving the growth of this market.

Based on applications, the global Vaccine Adjuvants Market is segmented into research and commercial applications. Research applications are expected to account for the largest share of the market during the forecast period. Growth in this segment is driven by factors such as increasing need for better immunization for the increasing geriatric population and increasing government funding in research to meet the unmet needs for safe and effective vaccine adjuvants.

On the basis of application categories, the Vaccine Adjuvants Market is segmented into human and veterinary adjuvants. Adjuvants for humans are expected to account for the largest share of the global Vaccine Adjuvants Market in 2016 and are expected to grow at a higher CAGR in the application category segment.

The key players in the Vaccine Adjuvants Market include Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MPV Technologies (U.S.), and OZ Biosciences (France).

Browse Related Reports:

Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019.

http://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html

Veterinary / Animal Vaccines Market by Product (Livestock, Companion, Poultry, Equine, Porcine), Diseases (Rabies, Distemper, Foot & Mouth, Gumboro, Swine& Avian Influenza, Strangles) & Technology (Live attenuated, DNA, Inactivated) - Global Forecast to 2020.

http://www.marketsandmarkets.com/Market-Reports/animal-veterinary-vaccines-market-1233.html

About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
newsletter@marketsandmarkets.com